We noticed the two main risks to the bearish AUD view are that (1) the currency is dragged higher in a more sustained re-rating of the global growth outlook and that (2) better global news and some signs of housing resilience see the RBA play for time. We remain of the view that the RBA will ease a further 50bp in this cycle.
Since our NZD outlook piece in November 2016, the economy has continued to perform strongly in real terms. GDP growth was over 1% QoQ in Q3, which would see the economy rounding out the year with annual growth comfortably above 3%. Still, much of the upside surprise in activity indicators is owed to the positive supply shock from migration (refer above chart).
We expect that growth impulse to fade through 2017, which would deliver growth performance more in keeping with subdued inflation and would also remove some of the pressure on housing.
Hence, we foresee AUDNZD potential below 1.0350 upto 1.0235 levels in medium terms. Higher to 1.0425, mainly for valuation reasons. The cross remains well below fair value estimates implied by interest rates, commodity prices, and risk sentiment. However, we acknowledge Australia’s AAA downgrade risk, any such action likely to delay any return towards fair value during the next few months.


Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
BTC Flat at $89,300 Despite $1.02B ETF Exodus — Buy the Dip Toward $107K?
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Thailand Inflation Remains Negative for 10th Straight Month in January
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



